Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871079 | 0.96 | HTR6 (0.38) | HTR6 | |
| SCHEMBL1829431 | 0.90 | HTR6 (0.44) | HTR6 | |
| SCHEMBL3011186 | 0.89 | HTR6 (0.38) | HTR6 | |
| SCHEMBL3959219 | 0.89 | HTR6 (0.38) | HTR6 | |
| SCHEMBL8717579 | 0.85 | HTR6 (0.36) | HTR6 | |
| SCHEMBL236429 | 0.84 | HTR6 (0.36) | HTR6 | |
| SCHEMBL6274716 | 0.83 | HTR6 (0.37) | HTR6 | |
| SCHEMBL139587 | 0.80 | HTR6 (0.41) | HTR6 | |
| SCHEMBL1427870 | 0.80 | HTR6 (0.36) | HTR6 | |
| SCHEMBL4823168 | 0.79 | HTR6 (0.39) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | HTR6 420/4885CXCR4 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.